Uscom Limited was incorporated in December 1999.

The company was founded by its current CEO, Associate Professor Rob Phillips. The company's first patents were filed in June of 1998 with Uscom Inc being formed in 2006. The Uscom Sydney office opened in August of 2002. The first USCOM 1A device was completed in October 2002 and Uscom listed on the Australian Stock Exchange in December of 2003.


Executive Chairman: Associate Professor Rob Phillips
Non Executive Director: Ms Sheena Jack
Non Executive Director: Mr Christian Bernecker
Non Executive Director: Mr Chao Xian (David) He

Company mission:

Uscom is a publicly listed cardiovascular medical technology company providing premium noninvasive technologies to clinicians to improve clinical care and health outcomes, and to grow shareholder wealth.

Primary product:

The USCOM 1A, (Ultrasonic Cardiac Output Monitor), the gold standard device for improved management of fluid, sepsis, heart failure and hypertension.

The Uscom BP+, is the gold standard supra systolic oscillometric central blood pressure technology which is improving diagnosis and treatment of hypertension and cardiovascular disease.

Business Overview:

Uscom is a global developer and manufacturer of novel cardiovascular technologies. The company has identified several substantial profit opportunities in devices sales, consumables and services arising from its products. Uscom has a sound product pipeline based on an expanding patent portfolio.

Business Objective: To create shareholder value through to worldwide commercialisation of Uscom's technology and to establish Uscom products as a global standard of medical practice.